论文部分内容阅读
目的:了解中药注射剂的临床使用及药品不良反应(ADR)发生情况,为临床安全合理用药提供参考。方法:统计我院2004～2007年中药注射剂的销售金额、用药频度(DDDs)、日均药费(DDC),及同时段中药注射剂的ADR报告情况。结果:2004～2007年用药金额排名前4位的药物是苦黄注射液、舒肝宁注射液和康莱特注射液、康艾注射液。用药频度排序前3位的是苦黄注射液、舒肝宁注射液、香丹注射液。抗癌中成药用药频度逐年上升。注射剂不良反应报表占中成药ADR报表的75.43%。舒肝宁注射液的ADR报告较多。结论:我院中药注射剂用药频度与用药金额基本同步。使用时应加强观察以减少ADR的发生。
Objective: To understand the clinical use of traditional Chinese medicine injections and the occurrence of adverse drug reactions (ADRs), and to provide reference for clinical safe and rational drug use. Methods: The sales amount, DDDs, DDCs, and ADR reports of TCM injections at the same time were recorded in our hospital from 2004 to 2007. RESULTS: The top 4 drugs for the 2004 to 2007 dose were Kuhuang injection, Shuganing injection, Kanglaite injection and Kangai injection. The top 3 in terms of frequency of application were Kuhuang injection, Shuganing injection, Xiangdan injection. The frequency of anti-cancer proprietary Chinese medicines has increased year by year. The injection adverse reaction report accounted for 75.43% of the Chinese medicine ADR report. Shuganing injection has more ADR reports. Conclusion: The frequency of medication and the amount of medication used in our hospital are basically in sync. Use observations should be strengthened to reduce the occurrence of ADR.